Skip to main content
    H

    Harrow Health Inc (HROW)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $29.09
    -1.03 (-3.42%)

    Market Cap: $1.13B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Harrow Health Inc (HROW) Earnings: Report Dates and Results

    Updated Nov 9, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Harrow Health (HROW) is confirmed to report earnings on Mar 1, 2027, after the close. In the quarter ended Sep 30, 2026, Harrow Health reported EPS of $0.12, below the $0.13 estimate. It beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    50%(18/36)
    Avg Surprise
    -20.26%

    Upcoming Estimates

    Reports Mar 1, 2027 after closePeriod ending Dec 31, 2026
    EPS Consensus$0.58
    Range$0.33 - $0.79
    11 analysts
    Revenue Consensus
    $139.31M
    Range$132.51M - $147.60M
    11 analysts
    Reports May 10, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.51
    Range-$0.51 - -$0.51
    1 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.10-410.0%
    60d ago-$0.10-410.0%
    30d ago-$0.10-410.0%
    7d ago-$0.15-251.7%
    Current-$0.51
    Revenue Consensus
    $89.44M
    Range$84.91M - $96.60M
    3 analysts

    Next Report

    HROW has a confirmed report date of Mar 1, 2027, after the close. Analysts' consensus for the quarter ending Dec 31, 2026 is 114.8% above the $0.27 reported for the quarter ended Dec 31, 2025.

    HROW Earnings Call

    The latest HROW earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 36 quarters below that had an estimate, HROW beat 18, missed 16 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $99.30M, up 38.6% from $71.64M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.12$0.13$0.12 - $0.48-7.69%Miss-63.6%40 up, 3 downNov 9, 2026$99.30M
    Jun 30, 2026-$0.34-$0.23-$0.50 - -$0.02-47.83%Miss-241.7%30 up, 1 downAug 10, 2026$70.66M
    Mar 31, 2026-$0.74-$0.33-$0.33 - -$0.33-124.24%MissN/A10 up, 1 downMay 11, 2026$44.20M
    Dec 31, 2025$0.27$0.39N/A-31.07%Miss-33.1%21 up, 2 downMar 2, 2026$89.09M
    Sep 30, 2025$0.33$0.29$0.18 - $0.36+13.79%BeatN/A31 up, 0 downNov 10, 2025$71.64M
    Jun 30, 2025$0.24$0.04N/A+500.00%BeatN/A40 up, 0 downAug 11, 2025$63.74M
    Mar 31, 2025-$0.38$0.01-$0.01 - $0.02N/AN/AN/A30 up, 2 downMay 8, 2025$47.83M
    Dec 31, 2024$0.40$0.13$0.06 - $0.24+207.69%BeatN/A31 up, 0 downMar 27, 2025$66.83M
    Sep 30, 2024-$0.05$0.07N/A-171.43%MissN/A40 up, 0 downNov 13, 2024$49.26M
    Jun 30, 2024-$0.06-$0.11N/A+45.45%BeatN/A40 up, 0 downAug 7, 2024$48.94M
    Mar 31, 2024-$0.28-$0.25-$0.27 - -$0.06-12.00%MissN/A40 up, 0 downMay 13, 2024$34.59M
    Dec 31, 2023-$0.25-$0.04-$0.08 - -$0.02-525.00%Miss-725.0%30 up, 0 downMar 19, 2024$36.35M
    Sep 30, 2023-$0.09$0.03-$0.05 - $0.15-400.00%MissN/A30 up, 0 downNov 13, 2023$34.27M
    Jun 30, 2023-$0.02-$0.04-$0.12 - $0.03+50.00%Beat-300.0%31 up, 0 downAug 9, 2023$33.47M
    Mar 31, 2023-$0.03-$0.06-$0.10 - -$0.03+50.00%Beat-200.0%30 up, 1 downMay 11, 2023$26.10M
    Dec 31, 2022$0.04-$0.12-$0.15 - -$0.05+133.33%BeatN/A30 up, 0 downMar 23, 2023$20.33M
    Sep 30, 2022-$0.20-$0.03-$0.04 - $0.04-566.67%Miss-600.0%40 up, 0 downNov 14, 2022$22.82M
    Jun 30, 2022$0.01$0.01N/A0.00%In line-88.9%N/A0 up, 0 downAug 9, 2022$23.32M
    Mar 31, 2022$0.03-$0.04-$0.05 - $0.00+175.00%Beat-66.7%40 up, 0 downMay 5, 2022$22.12M
    Dec 31, 2021-$0.27-$0.04-$0.10 - $0.08-575.00%Miss-775.0%4N/AMar 10, 2022$20.19M
    Sep 30, 2021$0.04-$0.03-$0.17 - $0.07+233.33%Beat0.0%4N/ANov 9, 2021$18.71M
    Jun 30, 2021$0.09$0.04N/A+125.00%BeatN/A2N/AAug 10, 2021$18.13M
    Mar 31, 2021$0.09$0.02N/A+350.00%BeatN/A2N/AMay 11, 2021$15.44M
    Dec 31, 2020$0.04$0.04-$0.01 - $0.050.00%In line-60.0%2N/AMar 8, 2021$40.81M
    Sep 30, 2020$0.04-$0.09-$0.10 - $0.17+144.44%BeatN/A2N/ANov 9, 2020N/A
    Jun 30, 2020-$0.14-$0.17N/A+17.65%BeatN/A2N/AAug 10, 2020$8.06M
    Mar 31, 2020-$0.04-$0.02-$0.50 - -$0.01-100.00%MissN/A2N/AMay 11, 2020N/A
    Dec 31, 2019$0.10$0.06-$0.02 - $0.13+66.67%Beat-87.0%2N/AMar 13, 2020$12.60M
    Sep 30, 2019-$0.29-$0.04N/A-625.00%MissN/A2N/ANov 13, 2019$12.76M
    Jun 30, 2019-$0.05-$0.06N/A+16.67%Beat-145.5%2N/AAug 14, 2019$13.52M
    Mar 31, 2019-$0.04-$0.12-$0.15 - $0.12+66.67%BeatN/A2N/AMay 9, 2019$12.29M
    Dec 31, 2018$0.77$0.34N/A+126.47%BeatN/AN/AN/AMar 12, 2019$22.12M
    Sep 30, 2018-$0.12-$0.09N/A-33.33%MissN/AN/AN/ANov 13, 2018N/A
    Jun 30, 2018$0.11-$0.12N/A+191.67%BeatN/AN/AN/AAug 6, 2018$10.38M
    Mar 31, 2018-$0.17-$0.16N/A-6.25%MissN/AN/AN/AMay 15, 2018$8.87M
    Dec 31, 2017-$0.13N/AN/AN/AN/AN/AN/AN/AMar 8, 2018$7.34M
    Sep 30, 2017-$0.28N/AN/AN/AN/AN/AN/AN/ANov 14, 2017$6.48M
    Jun 30, 2017-$0.26N/AN/AN/AN/AN/AN/AN/AAug 10, 2017$6.86M
    Mar 31, 2017-$0.21-$0.19N/A-10.53%MissN/AN/AN/AMay 10, 2017$6.10M
    Dec 31, 2016-$0.30-$0.28N/A-7.14%MissN/AN/AN/AMar 21, 2017$5.79M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.46, up 4475.0% from the year before. It was -$1.26 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.46+4475.0%
    Dec 31, 2024$0.01N/A
    Dec 31, 2023-$0.39N/A
    Dec 31, 2022-$0.12N/A
    Dec 31, 2021-$0.05N/A
    Dec 31, 2020-$0.10N/A
    Dec 31, 2019-$0.28-147.5%
    Dec 31, 2018$0.59N/A
    Dec 31, 2017-$0.88N/A
    Dec 31, 2016-$1.26N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,600 words across 14 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,62414
    2026Q2Jun 30, 20268,86913
    2026Q1Mar 31, 20267,04413
    2025Q4Dec 31, 202510,88113
    2025Q3Sep 30, 20259,09513
    2025Q2Jun 30, 20256,82611
    2025Q1Mar 31, 20256,0949
    2024Q3Sep 30, 20245,2258

    2026Q3 Earnings Call

    Opening remarks

    Michael Biega Vice President of Investor Relations and Communications Thank you, operator. Good morning, and welcome to Harrow's Third Quarter 2026 Earnings Conference Call. My name is Mike Biega, Vice President of Investor Relations and Communications. The company's remarks may include forward-looking statements within the meaning of federal securities laws. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Harrow's control, including risks and uncertainties described from time to time in its SEC filings, such as the risks and uncertainties related to the company's ability to make commercially available its FDA-approved products and compounded formulations and technologies, and FDA approval of certain drug candidates in a timely manner or at all. For a list and description of those risks and uncertainties, please see the Risk Factors section of the company's most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission. Harrow's results may differ materially from those projected. Harrow disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of today. Additionally, Harrow will refer to non-GAAP financial metrics, specifically adjusted EBITDA. A reconciliation of any non-GAAP measures with the most directly comparable GAAP measure is included in the company's earnings release and letter to stockholders, both of which are available on the website. Joining me on today's call are Mark L. Baum, Founder, Chairman and Chief Executive Officer; Andrew Boll, President and Chief Financial Officer; Patrick Sullivan, Chief Commercial Officer; and Amir Shojaei, Chief Scientific Officer. With that, I would like to turn the call over to Mark. Mark?

    Mark Baum Founder, Chairman and CEO Thanks, Mike, and good morning, everyone. Last quarter, I was clear. Our priority was turning the demand we were building into revenue. In the third quarter, that's exactly what happened, and it's the clearest sign yet that the second half is playing out as we expected. Demand is growing across key products. Our expanded commercial team is getting more productive every month, and we're reaffirming our full-year revenue guidance. We're continuing our momentum, and I expect the fourth quarter to be the strongest quarter in Harrow's history. I also believe you will see our momentum continue into 2027. You see it in VEVYE, which delivered record revenue as our expanded sales force matures and begins to deliver improved prescription economics. You see it in TRIESENCE, which had its strongest quarter under Harrow ownership. And you see it in IHEEZO, which heads into its historically strongest quarter with new clinical evidence from QUELL.

    Frequently Asked Questions About HROW

    When is Harrow Health's next earnings date?

    Harrow Health's next earnings report is confirmed for Mar 1, 2027, after the close.

    Did HROW beat earnings estimates last quarter?

    No. Harrow Health reported EPS of $0.12 for the quarter ended Sep 30, 2026, below the $0.13 estimate by 7.69%.

    What EPS do analysts expect from HROW next quarter?

    The consensus EPS estimate for Harrow Health for the quarter ending Dec 31, 2026 is $0.58 from 11 analysts, with estimates from $0.33 to $0.79.

    How often does HROW beat earnings estimates?

    Harrow Health beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate, with an average surprise of +42.40%.

    Does HROW report before or after the market opens?

    Harrow Health is confirmed to report on Mar 1, 2027, after the market closes.